Trials / Completed
CompletedNCT01698333
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 122-0551 | Applied twice daily for 2 weeks |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-03-01
- Completion
- 2013-07-01
- First posted
- 2012-10-03
- Last updated
- 2018-10-24
- Results posted
- 2018-09-26
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01698333. Inclusion in this directory is not an endorsement.